News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
29,103 Results
Type
Article (3571)
Company Profile (6)
Press Release (25526)
Section
Business (9669)
Career Advice (85)
Deals (1285)
Drug Delivery (14)
Drug Development (5023)
Employer Resources (10)
FDA (859)
Job Trends (800)
News (16314)
Policy (1345)
Tag
Academia (97)
Alliances (2700)
Alzheimer's disease (90)
Antibody-drug conjugate (ADC) (16)
Approvals (859)
Artificial intelligence (15)
Best Places to Work (571)
Biosimilars (26)
Breast cancer (22)
Cancer (145)
Career advice (74)
Cell therapy (21)
Clinical research (4013)
Collaboration (51)
COVID-19 (218)
C-suite (22)
Data (77)
Diabetes (15)
Diagnostics (260)
Drug pricing (16)
Earnings (2386)
Events (2626)
Executive appointments (43)
FDA (904)
Funding (31)
Gene therapy (22)
GLP-1 (107)
Government (221)
Healthcare (612)
Immunology and inflammation (14)
Infectious disease (222)
Inflammatory bowel disease (14)
Interviews (10)
IPO (441)
IRA (9)
Job creations (257)
Job search strategy (69)
Layoffs (52)
Legal (285)
Liver cancer (13)
Lung cancer (25)
Lymphoma (20)
Manufacturing (17)
MASH (9)
Medical device (183)
Medtech (183)
Mergers & acquisitions (857)
Metabolic disorders (64)
Multiple sclerosis (11)
Neurodegenerative disease (11)
Neuroscience (129)
NextGen: Class of 2025 (240)
Non-profit (175)
Northern California (106)
Obesity (43)
Opinion (28)
People (4061)
Phase I (1174)
Phase II (1619)
Phase III (1646)
Pipeline (47)
Podcasts (11)
Policy (14)
Postmarket research (303)
Preclinical (360)
Rare diseases (20)
Real estate (217)
Regulatory (976)
Research institute (114)
Resumes & cover letters (12)
Schizophrenia (10)
Series A (10)
Southern California (62)
Startups (206)
The Weekly (11)
United States (622)
Vaccines (33)
Weight loss (38)
Date
Today (4)
Last 7 days (21)
Last 30 days (111)
Last 365 days (1465)
2025 (216)
2024 (1501)
2023 (1509)
2022 (3088)
2021 (2746)
2020 (2389)
2019 (1744)
2018 (1421)
2017 (1444)
2016 (1329)
2015 (1635)
2014 (1182)
2013 (1029)
2012 (1158)
2011 (1243)
2010 (1175)
Location
Africa (67)
Arizona (12)
Asia (1357)
Australia (223)
California (204)
Canada (28)
China (18)
Connecticut (15)
Europe (6413)
Illinois (22)
Indiana (12)
Maryland (10)
Massachusetts (110)
Minnesota (9)
New Jersey (30)
New York (72)
North Carolina (15)
Northern California (106)
Pennsylvania (10)
South America (62)
Southern California (62)
Washington State (76)
29,103 Results for "roche boehringer mannheim".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.
March 3, 2025
·
2 min read
·
Tristan Manalac
Earnings
Roche to Stay ‘Disciplined’ With Deals in 2025
For 2025, Roche will continue a careful approach to high-priced deals, putting science at the center of its business development decisions, executives said Thursday.
January 30, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary fibrosis—nearly six months after achieving a similar feat in idiopathic pulmonary fibrosis. Boehringer plans to submit for FDA and other global approvals in both indications.
February 10, 2025
·
2 min read
·
Heather McKenzie
Collaboration
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
On Thursday, Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.
January 10, 2025
·
2 min read
·
Tristan Manalac
Schizophrenia
Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug price negotiation program.
January 17, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
February 13, 2025
·
3 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Roche Nears Completion of Poseida Acquisition Worth Up to $1.5B
In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.
January 8, 2025
·
3 min read
·
Tristan Manalac
Immunology & inflammation
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to develop and commercialize therapies for an undisclosed autoimmune disease.
December 3, 2024
·
1 min read
·
Heather McKenzie
Press Releases
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
February 10, 2025
·
7 min read
Drug development
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
September 24, 2024
·
4 min read
·
Heather McKenzie
1 of 2,911
Next
